A New Method for Determining Gastric Acid Output Using a Wireless Capsule

酸相关疾病有很多，通常需要长期治疗和维护。 这些疾病中的许多没有症状，因此难以诊断和治疗。胃分析是胃酸排出量的定量测量，是酸相关疾病诊断和治疗反应持续评估的重要工具。 目前，胃分析需要一个技术上困难的程序，通过鼻胃管使用胃抽吸，这是昂贵的，侵入性的，对病人来说不舒服。 最近推出了SmartPill，这是一种一次性药丸，可以测量整个胃肠道的pH值，温度和压力。 我们最近证明，SmartPill胃酸分析方法是一种非侵入性，准确和可重复的方法，用于定量测量健康受试者的胃酸排出量。 我们目前正处于方案的第二阶段，研究已知胃酸相关疾病的患者，以评估SmartPill在表征和治疗胃酸相关疾病患者中的效用。 感兴趣的受试者将报告给NIH胃肠门诊进行评估。 受试者将在下一次抗分泌药物给药前立即使用胃抽吸物法进行胃部分析，然后使用SmartPill法。结果将包括定量测量胃酸相关疾病患者单位时间内的胃酸排出量，以及评估接受各种抗分泌药物治疗的患者的胃酸抑制情况。 我们在研究的这一阶段招募患者的工作大约进行到一半，因此目前还没有任何成果可以报告。

Acid related disorders are numerous and often require chronic treatment and maintenance. Many of these diseases are without symptoms and therefore difficult to diagnose and treat. Gastric analysis is the quantitative measurement of gastric acid output and is a critical tool for the diagnosis of acid related disorders and the ongoing assessment of therapy response. At present gastric analysis requires a technically difficult procedure, using gastric aspiration through a nasogastric tube, that is costly, invasive, and uncomfortable for patients. Recently there is introduction of the SmartPill, which is a disposable pill that measures pH, temperature, and pressure throughout the GI tract. We have recently demonstrated that the SmartPill method of gastric acid analysis is a non-invasive, accurate and reproducible method for the quantitative measurement of gastric acid output in healthy subjects. We are presently in the second phase of the protocol studying patients with known acid related disorders to assess the utility of the SmartPill in characterizing and treating patients with gastric acid related disorders. Interested subjects will report to the NIH outpatient gastrointestinal clinic for evaluation. Subjects will have gastric analysis just before their next dose of anti-secretory medication using the gastric aspirate method followed by the SmartPill method. Outcomes will include a quantitative measurement of gastric acid output in unit time in patients with acid related disorders, and the assessment of acid suppression in patients treated with a variety of anti-secretory medications. We are approximately midway in our enrollment of patients in this phase of the study and therefore there are no accomplishments that can be reported at this time.